February 5, 2014 / 5:06 PM / 4 years ago

BRIEF-Innate Pharma buys rights to drug from Novo Nordisk

Feb 5 (Reuters) - Innate Pharma SA : * Buys full rights to anti-nkg2a checkpoint inhibitor from Novo Nordisk

* Novo Nordisk to reinforce its equity stake in Innate Pharma * Anti-nkg2a is a first-in-class therapeutic mab that is phase II ready * Novo nordisk will receive 2 million euros in cash and 600,000 shares for

licencing anti-nkg2a to Innate * Novo eligible to a total of 20 million euros in potential milestones and

single-digit tiered royalties on future sales * For more news, please click here

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below